id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-D-2818-0044,FDA,FDA-2015-D-2818,"Rare Diseases: Considerations for the Development of Drugs and Biological
Products; Guidance for Industry; Availability",Notice,Notice of Availability,2023-12-26T05:00:00Z,2023,12,2023-12-26T05:00:00Z,,2023-12-26T14:43:28Z,2023-28310,0,0,0900006486359d43
FDA-2015-D-2818-0045,FDA,FDA-2015-D-2818,Rare Diseases: Considerations for the Development of Drugs and Biological Products; Guidance for Industry - Final Guidance,Other,Guidance,2023-12-26T05:00:00Z,2023,12,2023-12-26T05:00:00Z,,2025-12-31T10:00:23Z,,1,0,090000648635a545